What 2.5 mg of tirzepatide is for — and why it matters

Why every tirzepatide patient starts at 2.5 mg, regardless of how much weight they want to lose

The SURMOUNT-1 trial, published in the New England Journal of Medicine, tested tirzepatide at 5 mg, 10 mg and 15 mg against placebo across 72 weeks in adults with obesity. The highest dose produced an average body-weight reduction of around 20–21%. None of those participants, however, started at 15 mg. Every arm of the trial began at 2.5 mg tirzepatide, stepped up in four-week increments. That structure was not a formality, it was pharmacological design.

Tirzepatide activates both the GIP and GLP-1 receptors, two gut-hormone pathways involved in appetite signalling and gastric emptying. Slowing gastric emptying is part of how the medicine reduces hunger, but that same mechanism is responsible for the nausea and digestive disruption that hits new users. Starting at 2.5 mg keeps those effects manageable while the gut adapts. Think of it less as a low dose and more as a calibration week, repeated four times.

The NHS medicines page for tirzepatide describes this schedule clearly: the starting strength exists to reduce early side effects, not to produce the weight-loss results you will eventually see at a higher maintenance dose. Patients who try to skip ahead (sometimes after reading about the full-dose results) tend to experience more nausea, not faster progress.

What the 2.5 mg period actually feels like, and what it means for your first month

For most people, the first four weeks on 2.5 mg tirzepatide are about noticing small shifts rather than dramatic ones. Appetite may feel slightly reduced. Some people report feeling fuller more quickly at meals. But the headline weight-loss figures from clinical trials reflect months of treatment at maintenance doses, not what happens in week one.

Side effects during the 2.5 mg period are common. Nausea is the most frequently reported; loose stools, indigestion and fatigue also appear in the data. These are generally mild to moderate and tend to settle within the first couple of weeks for most users. Staying well hydrated helps. Eating smaller, lower-fat meals during this period (particularly around injection day) is a practical step many people find useful.

Timing matters in a practical sense too. If your first pen arrives just before a bank holiday or a trip away, your prescriber can advise on how to handle the schedule. It is worth building some flexibility into the first few weeks rather than assuming every four-week step will land on a convenient day.

If side effects feel unmanageable or you have concerns about how your body is responding, contacting your prescriber is always the right move. At nume, aftercare is available seven days a week, details on reaching the team are here.

Moving from 2.5 mg to the next dose, and what the evidence says about titration

After four weeks, a prescriber will typically move tirzepatide to 5 mg. The five-step licensed schedule (2.5, 5, 7.5, 10, 12.5 and 15 mg) is described in the prescribing information published on the electronic Medicines Compendium, and each increment follows roughly the same logic as the first: allow the body time to adjust before going higher.

The pace is not automatic. If side effects at 1 mg tirzepatide are still significant at the four-week mark, a prescriber may extend that period rather than titrate on schedule. That is a clinical call, made with knowledge of the individual patient. What the evidence from SURMOUNT-1 tells us is that the benefits compound over time at each successive dose, the biggest weight reductions appear in the trial's later months, not the first few weeks.

For a fuller picture of what comes next, the 5 mg tirzepatide page covers what changes at the second dose step and what to expect from that phase. Understanding how Mounjaro works across the full schedule can also help set realistic expectations from the outset. If you are thinking about private treatment and wondering about the cost context, the weight-loss treatment overview sets out what is included in a private prescription pathway.

Who the 2.5 mg starting dose is licensed for, and what a prescriber weighs up

The licensed indication for tirzepatide (Mounjaro) covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, dyslipidaemia, obstructive sleep apnoea, type 2 diabetes or cardiovascular disease. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone does not determine suitability, the prescriber reviews the full clinical picture, including any contraindications.

Tirzepatide is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. People with a history of medullary thyroid carcinoma or pancreatitis require careful prescriber discussion before starting. Those who have previously tolerated an earlier strength and are considering stepping up can find relevant guidance on the tirzepatide 7.5 mg page.

At nume, every new patient goes through a same-day clinical review by a GPhC-registered Independent Prescriber, including photo-ID verification and live weight confirmation. A prescriber, not an algorithm, reads your answers. The FAQs page covers common eligibility questions in more detail.

If you would like to find out whether tirzepatide is clinically appropriate for you, the right next step is a consultation rather than a web search. Check your eligibility through a free consultation, there is no obligation, and the clinical review happens the same day.